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Natural  killer  (NK) ~ activity  has  been  implicated as  an  important  immune 
mechanism  in  the  prevention  of experimental  tumor  metastasis  in  both  the 
mouse (1-3)  and  the  rat  (4). 2 NK  activity  has  also  been  suggested  to  be  an 
important component of the immune response against virus-infected cells (5-7). 
In the human (8) and the rat (9), this NK activity has been closely associated with 
large granular lymphocytes (LGL). In both species, it has been possible to enrich 
for LGL, and concomitantly for NK activity, by fractionation of peripheral blood 
lymphocytes (PBL) on discontinuous gradients of Percoll. The ability to consist- 
ently obtain LGL in high purity has allowed studies of LGL to proceed steadily 
for both the rat (4,  10-12)  and the human (13-15).  However, the isolation of 
highly enriched LGL from the mouse has been more difficult (16-18). Generally, 
the LGL purity obtained by Percoll fractionation of mouse spleen cells has been 
only 20-40%,  even  when two sequential  gradients  have  been  employed (17). 
Higher  purity  of mouse  LGL  has  been  obtained  from  blood  (17);  however, 
studies  of these  cells  have  been  limited  by  the  relatively  low  yield  of LGL. 
Similarly, LGL with NK activity have been isolated from the mucosa of the small 
intestine of mice (19, 20). These cells were morphologically and phenotypically 
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similar to LGL obtained from spleen, except that the gut LGL were more readily 
depleted by treatment with anti-Thy-1.2  + antibody and complement than were 
splenic LGL. 
Recently, we have linked increased resistance to metastasis  formation in the 
lungs  and  livers of mice  treated  with  the  biological  response  modifier (BRM) 
maleic  anhydride  divinyl  ether  (MVE-2)  to  the  presence  of augmented  NK 
activity localized in these organs. 3 In the present paper, we describe the nature 
of the activated NK effector cells isolated from the liver. Specifically, we report 
the isolation, enrichment, surface phenotype, and cytolytic activity of activated 
LGL from perfused livers of mice treated with MVE-2 or heat-killed Corynebac- 
terium parvum.  The results demonstrate that large numbers  of highly purified 
LGL can be obtained from the livers of BRM-treated mice. Further, the results 
suggest that at least some BRMs may induce antiviral or antimetastatic therapeu- 
tic effects through augmentation of organ-associated natural immunity. 
Materials and Methods 
Animals.  Inbred male and female C57BL/6N mice were obtained from the Animal 
Production Area, National Cancer Institute-Frederick Cancer Research Facility, Freder- 
ick, MD, and were routinely used at 7-10 wk of age. 
Tumor  Cell  Lines.  Tumor  cells  used  as  targets  in  these  studies  were  the  YAC-1 
lymphoma of A/Sn origin (21), the L5178Y lymphoma of DBA/2 mice (22), the P815 
mastocytoma of DBA/2  mice (23),  the  MBL-2 lymphoma of C57BL/6 mice (24), the 
WEHI-164  fibrosarcoma of BALB/c  mice  (25),  and  Meth  A,  a  chemically induced 
fibrosarcoma of BALB/c mice (26).  The cells  were maintained in continuous in  vitro 
culture in  RPMI  1640 (M.  A.  Bioproducts, Walkersville, MD) supplemented with  10% 
fetal bovine serum (FBS) (Sterile Systems, Logan, UT),  100 U/ml of penicillin and  100 
#g streptomycin (P/S), 50 ug/ml gentamycin (Schering Corp., Kenilworth, NJ), and 300 
~g/ml L-glutamine (complete medium). The RPMI  1640 and FBS batches were demon- 
strated by Limulus amebocyte test (M. A. Bioproducts) to contain <0.1 ng]ml of lipopol- 
ysaccharide (LPS). All tumor cell lines have been shown to be free of mycoplasma (Flow 
Laboratories, McLean, VA), as well as the following viruses: Sendai, pneumonia virus of 
mice, minute virus of mice, lymphocytic choriomeningitis virus, polyoma virus, mouse 
hepatitis virus, mouse adenovirus, Ectromelia virus, and lactic dehydrogenase elevating 
virus (Animal Health Diagnostic Laboratory, National Cancer Institute-Frederick Cancer 
Research Facility). 
Radioisotopic  Labeling  Procedures.  ~Cr  was  obtained  from  New  England  Nucl~ear 
(Boston, MA)  at a  concentration of 1 mCi/ml.  Labeling with  51Cr was  performed by 
incubating 5 ×  10  ~ tumor cells in 0.5 ml complete medium at 37°C with 100 uCi 5~Cr for 
1 h. Labeled cells were then washed two times in 50 ml complete medium and resuspended 
to the proper concentration. 
Biological Response Modifiers.  NK activity was augmented by the intravenous or intra- 
peritoneal injection of 25 mg/kg of the pyran copolymer MVE-2, or by the intraperitoneal 
injection of 25 mg/kg of the pyran copolymer MVE-2, by the intraperitoneal injection of 
35 mg/kg formalin-killed C. parvum (strain CN 6134; Burroughs Wellcome, Inc., Research 
Triangle Park, NC). Both MVE-2 (27) and C. parvum were injected 1-12 d before harvest, 
depending on the nature of various experiments. 
Anti-Asialo  GMl Serum.  Rabbit antiserum to asialo GMl (asGMi) was obtained from 
Wako Pure Chemical Co., Dallas, TX. The specificity of such antisera for asGM~ has been 
previously documented (28). The standard regimen of NK suppression in vivo has been 
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determined such that 0.2 ml of a  1:20 dilution of anti-asGM~ serum eliminates >80% of 
NK activity in  blood and  spleen.  Optimal suppression of NK activity occurs when  the 
antisera are administered 1-3 d before assay. 
Isolation  of Effector  Cells from the Liver.  Cells were isolated from the liver using the 
method of Richman et al.  (29),  with  some modifications.  Mice were killed by cervical 
dislocation; the peritoneal cavity was aseptically exposed and the inferior vena cava was 
cut to allow rapid exsanguination. Next, the hepatic portal vein was exposed and cathe- 
terized with a  21-gauge butterfly needle, and 8-10 ml prewarmed RPMI  1640 medium 
with  5%  fetal bovine serum (FBS)  was slowly injected to flush blood from the hepatic 
vasculature. When properly performed, the perfused liver was completely blanched. Any 
livers or lobes that were not completely blanched  were discarded.  The liver was then 
excised and the gallbladder was removed. Livers were then extensively minced into small 
pieces with surgical scissors,  gently forced through 50-gauge stainless steel mesh using a 
sterile syringe plunger, and placed at 4°C in a  50-ml polypropylene tube. This extract 
was  centrifuged  at  600  g  for  10  min,  and  the  supernatant  was  removed.  10  ml  of 
prewarmed enzyme solution, containing 0.05% collagenase type II (Sigma Chemical Co., 
St. Louis, MO) and .500 U/ml DNAase type I (Sigma Chemical Co.) in Hanks' balanced 
salt solution (HBSS) plus 5% FBS,  was added per milliliter of packed liver extract. The 
enzyme extract mixture was incubated in a 37°C water bath for 8-10 min with constant 
agitation,  and  the  enzymatic digest  washed two times in  cold  HBSS (without  Ca  ++ or 
Mg++). When  properly performed, this procedure yields a  cell pellet that contains few 
erythrocytes, which indicates that the isolated cells are not substantially contaminated by 
iymphocytes from the peripheral blood. The enzymatically digested liver was then resus- 
pended in a minimal amount of cold HBSS and 30% metrizamide in Gey's solution at a 
final ratio of 7 parts metrizamide per 5 parts packed liver digest. 3-5 ml of the mixture 
was  transferred  to  15-mi  conical  tubes  and  overlaid  with  1.5  ml  PBS.  This one-step 
metrizamide gradient was then centrifuged at 1,400 g for 20 min at 4°C, the nonparen- 
chymal cell  layer was  carefully removed  from the  metrizamide  PBS  interface  with  a 
pasteur pipette, and the cells were washed two times in RPMI  1640 plus 5% FBS.  The 
composition of the nonparenchymal cells was then ascertained by Wright-Giemsa stain of 
a cytocentrifuge preparation (>95%  leukocytes), and the cells were resuspended to the 
desired  cell concentration  in  RPMI  1640  supplemented with  5%  FBS,  90  mM  Hepes 
buffer (M.  A. Bioproducts),  1 mM sodium pyruvate (Gibco Laboratories, Grand Island, 
NY), P/S, and L-glutamine (assay medium). 
Isolation  of LGL.  LGL were obtained after the metrizamide purification of mononu- 
clear cells from suspensions of enzymatically digested liver by a modification of separation 
procedures  previously  described  for  human  LGL  (8,  13,  14).  Briefly,  nonadherent 
lymphocytes were obtained by removal of adherent cells on nylon wool columns (37°C 
for 45 min) and the eluted cells (20-100 ×  108 cells/gradient) were then fractionated by 
centrifugation  at  300  g  for  30  min,  on  a  seven-step discontinuous  density  gradient 
(osmolarity, 290  mosmol) of Percoll  (Pharmacia  Fine  Chemicals,  Uppsala, Sweden)  at 
concentrations of 38.6, 47.6, 52.1, 56.6, 61.1, 65.6, and 70.1%. LGL were collected from 
the uppermost low-density fractions (fractions 1 and 2), while T  cells were collected from 
the high-density bottom fractions (fractions 4-6).  Cell preparations were evaluated for 
morphology by microscopic analysis of Giemsa-stained cytocentrifuge preparations. 
Assay for NK Cell-mediated Cytotoxicity.  Various numbers of spleen, liver, or peritoneal 
effector cells were mixed in quadruplicate with 5  ×  105 S~Cr-labeled  target cells in 96- 
well, round-bottomed microtiter plates (Linbro Scientific Co.,  Hamden, CT) in a  total 
volume of 0.2 mi assay medium. Plates were incubated for 4 h, supernatants were removed 
from wells by the Titertek automatic harvesting system (Flow Laboratories, McLean, VA), 
and  the  radioactivity  was  counted  in  a  gamma counter  (Beckman  Instruments,  Inc., 
Fullerton, CA). Control cultures consisted of 5~Cr-labeled  target cells incubated in assay 
medium alone. 
The percentage specific release of 5~Cr was calculated by the following formula: Percent 
specific cytoxicity =  [(mean cpm released from test well -  mean cpm released from target 1434  ISOLATION  OF  LARGE  GRANULAR  LYMPHOCYTES  FROM  LIVER 
cells alone)/(mean total cpm)]  x  100.  Results are also expressed as lytic units (LU)/107 
cells, with LU being the number of effector cells required to lyse 30% of the target cells. 
Immunofluorescence Experiments.  Immunofluorescence (IF) of LGL and T  cell surface 
antigens was detected by primary incubation with monoclonal antibodies (MAb), whenever 
available followed by a secondary incubation with a fluoresceinated secondary antibody. 
LGL and T cell-enriched suspensions obtained from Percoll fractions (14) were adjusted 
to 2 x  107 cells/ml and 50 #1 of cells (1 x  106 cells) were incubated with 10-50 ~1 MAb, 
depending on the source and concentration. Cells plus antibody were incubated for 45 
min and then washed two times in a 2-ml vol of HBSS with bovine serum albumin (BSA) 
and NAN3. A second incubation with an appropriately titered fluoresceinated reagent was 
also done for 45 min. After incubation with the secondary antibody, the cells were again 
washed twice and suspended in 0.4 ml HBSS plus BSA plus NaN3  for flow cytometry 
analysis (FCA). For some MAb, isotype-specific developing reagents were used; however, 
in most cases, fluoresceinated, affinity-purified goat antibody to mouse Ig (F1-GAMIg), 
goat anti-rabbit Ig (FI-GARablg), or goat anti-rat Ig (FI-GARatIg) were required for the 
secondary developing reagent.  FI-GARablg and FI-GARatlg were obtained as  F(ab')2 
fragments from Cappel Laboratories (Cochranville, PA). The other reagents have been 
described  elsewhere  (30)  and  were  obtained from  Dr.  B. J.  Fowlkes  (Laboratory of 
Microbial Immunity, National Institute of Allergy and Infectious Diseases, Bethesda, MD). 
The MAb reagents that were used, along with the source of the reagents and the pertinent 
references for these reagents, are indicated in the figure legends. 
FCA.  Immunofluorescence was analyzed on a  Cytofluorograf System 30-H  with a 
2150 computer (Ortho Diagnostic Systems Inc., Westwood, MA) that was modified to 
provide simultaneous measurement of forward and right angle light scatter (488 nm) and 
red (>600 nm) and green (530 nm) fluorescence. Cells were illuminated by a 4-W argon 
laser (Lexel Corp., Pa|o Alto, CA) emitting 500 mW of 488-nm light. Cells analyzed for 
IF were selected by forward light scatter, and dead cells, identified by the uptake of 
propidium iodide (red fluorescence), were excluded from green fluorescence analysis. A 
green  fluorescence histogram of 1,000  channel resolution was collected from 20,000 
viable cells for each sample analyzed. The percentage of positive cells was calculated by 
integration of the experimental and control (secondary fluoresceinated reagent alone) 
histogram. 
Statistics.  Statistical  analyses were performed by Student's t test. 
Results 
Augmentation  of NK Activity  in Spleen  and Liver after Administration  of MVE- 
2.  Because  our  previous  observations  demonstrated  a  relationship  between 
organ-associated NK activity in MVE-2-treated mice and resistance to metastasis, 3 
and since MVE-2 augments NK activity in the spleen (31), we were interested in 
determining whether  NK activity in  other  nonlymphoid organs was also aug- 
mented by MVE-2  treatment.  The experiment shown in  Fig.  1 demonstrated 
that  as  in  the  spleen,  liver  NK  activity peaked  at  3  d  after  the  intravenous 
injection of MVE-2.  However, the NK activity from the liver remained signifi- 
cantly (P <  0.05 to <  0.005) elevated through at least day 11, and, at the same 
effector-to-target ratios, was always higher than the activity seen with unfraction- 
ated spleen  cells.  The  relationship  in  NK  activity among unfractionated cells 
isolated from the liver at various times after MVE-2 treatment is better shown 
in Fig. 2. At 3 d after MVE-2 injection, high levels of specific cytotoxicity against 
the YAC-1  target cells (>40%) were observed even at effector-to-target ratios as 
low as  12:1.  These results are particularly impressive when one considers that 
this  level  of hepatic  NK  activity was  observed  with  unfractionated  leukocyte 
populations from the liver. WILTROUT  ET  AL.  1435 
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FIGURE 1.  Augmentation of NK activity  in  spleen  and  liver  following  administration  of 
MVE-2. Cells from spleen (m) and liver (i) were obtained as described in the Materials and 
Methods from normal C57 BL/6 mice or mice injected intravenously  1-11 d earlier with MVE- 
2. These cells were tested against  5tCr-labeled YAC-1 tumor cells for 4 h for assessment of 
NK activity. The effector-to-target ratio was 100:1. Splenic NK was significantly augmented 
(P < 0.01) only on day 3, while hepatic  NK was significantly augmented (P < 0.005-0.05) at 
all times tested. 
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FIGURE 2.  Augmentation of hepatic  NK activity by administration  of MVE-2. MVE-2 was 
administered  to  C57BL/6  mice  intravenously  1-11  before  harvest  of the  livers  for NK 
assessment. Leukocytes isolated from the livers were reacted at various effector-to-target ratios 
of 5~Cr-labeled YAC-1 cells. A, normal; O, 1 d; r-l, 3d; I, 5 d; O, 8 d; 0, 11 d. 
Augmentation  of Peritoneal  and Liver  NK Activity by Administration  of C.  par- 
vum.  Because  MVE-2  increased  resistance  to  metastasis 3  and  strongly  aug- 
mented  levels  of NK  activity  in  the  liver  (Figs.  1  and  2),  it  was  of interest  to 
determine  whether  other antimetastatic  BRMs would also augment  liver-associ- 
ated  NK activity.  The  results  shown  in  Fig.  3  demonstrate  that after C. parvum 
administration,  NK  activity  of leukocytes isolated  from  the  liver  reached  peak 
levels on day 3 and declined to normal levels by day 10. Significant augmentation 
ofcytotoxicity (P <  0.01 to <  0.05) was observed between days 1 and 8. Peritoneal 
NK  activity,  similar  to  the  liver-associated  NK  activity,  peaked  3-6  d  after  C. 1436  ISOLATION  OF  LARGE  GRANULAR  LYMPHOCYTES  FROM  LIVER 
t...-  >"  801 
40- 
I~  20- 
N 
0- 
0  1  3  6  8  10  12 
DAYS AFTER C. PARVUM ADMINISTRATION 
FIGURE 3.  Augmentation of peritoneal and liver NK activity by administration of C. parvura. 
C. parvura was administered intraperitoneally to C57BL/6 mice 1-12 d before the harvest of 
i~ecritoneal exudate or  liver-derived cells.  These cell populations were then incubated with 
r-labeled YAC-1  for 4  h and levels of NK activity were assessed  at an effector-to-target 
ratio of 50:1. Similar results were obtained at other ratios. Both peritoneal and hepatic NK 
was significantly augmented at 1, 3, and 6 d P <  0.01), as well as 8 d (P <  0.05). m, PEC; II, 
liver. 
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FIGURE 4.  Effects of MVE-2 and anti-asGM~ serum administration on NK and NC activities 
in the liver. Liver-derived mononuclear cells were isolated from normal mice (J), mice treated 
3 d earlier with MVE-2 and 1 d earlier with anti-asGMi serum (cross-hatched bar) or with just 
MVE-2 three days earlier (11). These cells were then tested against with 5tCr-labeled YAC-1 
for 4 h (NK) or with 51Cr-labeled  WEHI-164 for 18 h (NC). The effector-to-target ratio was 
50:1 for both NK and NC. Lysis of YAC-1 was significantly  augmented by MVE-2 (P <  0.01) 
and the MVE-2 augmentation was significantly reduced by anti-asGM~ serum treatment (P < 
0.01). 
parvum  administration  and  then  rapidly  declined.  The  results  indicate  that 
although  both MVE-2 and C. parvum augment  NK activity in the liver, the effect 
is more  transient  for C. parvum. 
Sensitivity  of Augmented  Liver NK Activity  to Anti-asGM]  Serum.  Spleen  and 
blood  NK activity has been previously shown (3,  28,  32,  33) to be sensitive to in 
vitro or in vivo treatment  with anti-asGM1 serum. This depression of NK activity 
by anti-asGM1 serum  has also been correlated  with an increase in metastasis (3). WILTROUT ET AL.  1437 
The study shown in Fig. 4 was designed to determine whether the cells mediating 
NK  activity  from  the  livers  of MVE-2-treated  mice  also  expressed  the  NK- 
associated marker asGM~. In this experiment, the MVE-2-augmented NK activity 
of liver-associated cells was reduced -65%  when anti-asGM1 serum was admin- 
istered  1  d  before assay.  These  results  demonstrate that  the augmented NK 
activity induced by MVE-2 in the liver could be significantly (P <  0.01) depleted 
by treatment in vivo with anti-asGMl serum. 
Since  natural  cytotoxic (NC)  cells  have also  been  implicated  as  antitumor 
effectors (26), we tested for the presence of NC activity in liver, and its modu- 
lation by MVE-2 and anti-asGM~ serum. Interestingly, the nonparenchymal cells 
obtained from normal liver tissue had considerable NC activity as assessed by 
lysis of WEHI-164  cells (Fig.  4).  However, in contrast to NK activity, the NC 
activity  from  the  liver  was  neither  augmented  by  MVE-2  nor  reduced  by 
treatment with anti-asGM~ serum (Fig. 4). 
Isolation  and Enrichment  of LGL from the Livers of MVE-2-treated  Mice.  The 
findings of augmented NK activity after BRM treatment led us to postulate that 
the liver would contain LGL, which have been characterized morphologically as 
the cells mediating NK activity (4,  8-13,  16-20).  Further, we postulated that 
since the NK activity of MVE-2-treated mice was higher in leukocytes isolated 
from the liver than  in  spleen or peritoneal cell isolates,  the liver-derived cell 
population  might  contain  a  high  percentage of LGL  that  could  be  used  for 
further enrichment of LGL. To test these postulates, we obtained leukocyte-rich 
preparations by metrizamide gradient fractionation of enzymatically dissociated 
livers from normal mice and from mice treated earlier with BRMs.  Routinely, 
-0.5-2.0  ×  106 total nonparenchymal cells were recovered per normal mouse, 
25-40% of which were macrophages (Kupffer cells, as characterized by phago- 
cytosis and esterase positivity) and 45-60% lymphocytes. After the administration 
of BRMs, the total number of cells recovered per mouse increased markedly to 
5-10  X  10  6 for MVE-2 and 5-20  ×  106 for C. parvum, depending on the time 
of BRM  administration.  In  spite  of this  increase  in  total  cell  number,  the 
percentages of macrophages and lymphocytes obtained from the livers of BRM- 
treated mice remained similar to those observed for normal control mice. 
Morphological characterization of the metrizamide gradient-purified leuko- 
cytes revealed that the percent LGL increased from 3-8%  in normal mice to 
10-15%  in  BRM-treated  mice.  The  total  number of hepatic  LGL  recovered 
from  BRM-treated  mice was  consistently in  the range  of 2.0-2.5  ×  106  per 
mouse compared with 0.05-0.2  ×  106 per normal mouse, a  10-50-fold increase 
(Table I). This increase in the number of LGL isolated from perfused liver (i.e., 
nonperipheral blood cells) was accompanied by an appreciable increase in the 
number of mononuclear cells observed in the tissues by histological examination 
of liver sections (Wiltrout, R. H., and C. W. Reynolds, manuscript in preparation). 
These cells were observed initially as perivascular cuffing and later were uni- 
formly distributed throughout the liver parenchyma. 
To  further  enrich  for  liver-derived  LGL,  metrizamide-purified leukocytes 
were  depleted  of adherent  cells  by  passage  over  nylon  wool  columns.  The 
resulting suspension obtained from normal livers contained an average of 10% 
LGL, while the nylon wool-passed leukocyte preparations from MVE-2-treated 1438  ISOLATION  OF  LARGE  GRANULAR  LYMPHOCYTES  FROM  LIVER 
TABLE  I 
Total Number of LGL Obtained from the Livers of Normal and 
BRM-treated Mice* 
Treatment  Total LGL ×  10r/liver  n 
None  0.05-0.2  10 
MVE-2  2.0-2.5  8 
C. parvum  2.0-2.5  6 
* Determined by enumeration of LGL in metrizamide gradient-purified 
leukocyte preparations obtained from enzymatically digested livers. The 
number of experiments (n) used to obtain the pooled data is shown for 
each treatment. 
TABLE  II 
Enrichment for Liver LGL and NK Activity by Depletion of Adherent Cells and Fractionation 
on Percoll Density Gradients 
Enrichment in 
Treatment in  vitro  Percent total cells that were:  Lytic units  Total LGL re- 
vivo*  (30%)0  covered per 
NW*  Percoll  LGL  LAL  LGL +  LAL  liver! 
None 
MVE-2 
MVE-2 + Anti- 
asGM~ 
+  --  10  13  23  3  5.5 X 10  ~ 
+  --  36  26  62  546  1.1 ×  106 
+  Fj  69  22  91  1,829  3.4 X 105 
+  F2  49  26  75  521  2.0 X 105 
+  F3  10  10  20  13  4.0 ×  104 
+  F4  5  5  10  0  7.1 ×  103 
+  --  18  27  45  215  1.1 ×  105 
* C57BL/6 mice were injected intravenously with 25 mg]kg MVE-2 three days before harvest. Some 
mice also received 0.2 ml of a 1:15 dilution of anti-asGM~ serum 1 d before harvest. 
* NW, nylon wool-nonadherent cells with adherent cells removed by incubation on  nylon wool 
columns as described in Materials and Methods. 
0 Percent specific release was assessed against YAC-1 and lytic units calculated per 1 x  10 7 cells. 
I Following nylon wool with or without Percoll gradient separation. 
mice  were  enriched  in  LGL  to  36%  (Table  II).  Most  of the  non-LGL  cells 
obtained  from  MVE-2-treated  mice  following  nylon  wool  passage  were  large 
agranular  lymphocytes  (LAL).  LAL  are  morphologically  similar  to  LGL,  but 
possess no visible azurophilic cytoplasmic granules and  may be related to  LGL 
(17,  34).  As with  the  LGL,  the percent  of these cells was consistently increased 
twofold  over  normal  mice  (Table  II).  Similar  results  were  obtained  when  C. 
parvum was used as the stimulus for augmenting  hepatic NK activity. 
Increases in the percentage  of LGL  isolatable from  the  lungs,  in addition to 
the liver, were also observed after MVE-2  treatment  (data not shown). 
Since the increase in number  and percentage of liver-associated LGL in MVE- 
2-treated mice correlated well with the augmented  NK activity (Table II), further 
enrichment  of LGL  by fractionation on discontinuous Percoll density gradients 
was  performed.  This  fractionation  resulted  in  even  higher  levels of both  LGL 
and  NK activity, with the cells from fraction  1 enriched  to 69%  LGL and those 
from  fraction  2  to  49%  of LGL.  Cells from  these  two  fractions accounted  for 
virtually all of the  NK activity seen.  In contrast,  fractions  3  and  4  were  mostly WILTROUT  ET  AL.  1439 
small lymphocytes, and had very low NK activity. Consistent with the marked 
reduction in NK activity, treatment with anti-asGM~ serum in vivo reduced both 
the percentage (from 36  to  18%) and total number of LGL (by 90%) isolated 
from the liver (Table II). 
Target Specificity of LGL Isolated  from Livers of MVE-2-treated Mice.  Selectivity 
of target cell lysis has been one of the classic characteristics used for the definition 
of NK activity and permits its discrimination from macrophage-mediated cyto- 
toxicity (35,  36).  To determine whether liver LGL mediated tumor lysis with 
the target selectivity expected for NK cells, we tested Percoll-enriched LGL from 
the livers of mice treated with MVE-2 against a panel of NK-sensitive and NK- 
resistant tumor cell lines (Fig. 5). Liver-derived LGL efficiently lysed YAC-1  in 
a  dose-dependent  manner,  even  at  effector-to-target ratios  as  low  as  0.7:1. 
Conversely, three NK-resistant tumor targets (P815, L5178Y, and MBL-2) were 
poorly lysed even at the highest effector cell concentration used, in spite of the 
fact that all are good targets for macrophages and cytotoxic T  cells (31). These 
studies demonstrate that liver-derived LGL from MVE-treated mice possess the 
cytotoxic specificity commonly attributed  to  NK cells, but not to cytotoxic T 
cells or macrophages. 
Surface Phenotype of LGL Isolated  from the Liver.  To further characterize the 
highly lytic LGL  obtained from the livers of mice treated with  MVE-2  or C. 
parvum, and to compare the surface phenotype of liver-derived LGL with that 
reported for other LGL populations,  Percoil-enriched LGL were analyzed for 
expression of cell surface markers by FCA.  Similar results were obtained with 
cells from mice treated with both BRMs (Table III). Examples of the FCA are 
shown in Fig. 6. Percoll-enriched, liver-derived LGL expressed Ly-5 and asGM~, 
antigens previously shown to be associated with murine NK cells (28,  32,  33, 
37-41),  in high amounts. Similarly, the fraction  1 liver LGL were positive for 
Qa-5  expression,  in  agreement with  previous  reports  on  the  mouse  NK  cell 
phenotype (39-41).  However, in contrast to the low Thy-l.2 phenotype previ- 
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FIGURE 5.  Target specificity of LGL isolated from livers of MVE-2-treated mice. Mice were 
injected intravenously with  MVE-2  3  d  before  harvest and  hepatic  LGL  were  isolated as 
described in Materials and Methods. The liver LGL from Percol] fraction 1 (69% LGL) were 
then tested against 5tCr-labeled YAC-1  (I-1), P815 (11), L5178Y (O), or MBL-2 (0) for 4 h  for 
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FIGURE 6.  Flow cytometry IF histograms of cell surface antigens. Percoll fractions of cells 
isolated from  the  liver of MVE-2-treated  mice,  enriched  for  LGL  (fraction  1)  or  small 
lymphocytes (fraction 4), were treated with MAb or rabbit antibody plus appropriate secondary 
fluorescent reagents. The reagents used were as follows: anti-Ly-5.1, (New England Nuclear), 
10 ~1 of 1:400-diluted ascites; anti-Qa5, clone B 16-167 obtained from Dr. Ulrich Hammerling 
(Sloan-Kettering Institute, New York), 50 gl of culture supernatant; directly fluoresceinated 
anti-Thy-  1.2 (Becton-Dickinson, Palo Alto, CA), 50 gl of 1:100-diluted stock; anti-Ly-  1.2 (New 
England  Nuclear),  10 #1 of 1:200-diluted ascites;  anti-Gma-l.2 hybridoma ascites obtained 
from  Dr.  Fung-Win Shen  (Sloan-Kettering Institute),  10  #1  of  l:200-diluted ascites.  Cell 
samples treated with MAb to Ly-5, Qa-5, Ly-1, and Gma-1 were subsequently treated with a 
polyvalent F1-GAMIg that also detects sIg. The background in fraction 1 with this reagent 
was 5.3%, whereas there were 29%  sIg  ÷ cells in fraction 4 (seen  in the lower right panel). 
When anti-asGM~ was used, F l-GARabIg  was used as the secondary reagent. The appropriate 
control histograms are indicated by the unfilled histograms in each panel. Cells in fraction 1 
were 99.8% Ly-5  +, 77% Qa-5  ÷, 75% Thy-1 ÷, 93% asGM~  ÷, 5% (net)  Lyt-1 ÷, and 97%  Gma- 
1  ÷ (with greater IF than the median control value).  By comparison, cells in fraction 4 were 
98.9% Ly-5  + (including 29% slg÷), 4% (net) Qa-5  +, 61.5% Thy-1 + (greater than channel 300), 
35.8%  asGMt  + (greater than channel  150), and 60.3%  Lyt-1 ÷ (net value with 29% slg  ÷ cells 
excluded). 
ously reported  for NK cells from  spleen or blood (26,  41-43),  the liver-derived 
LGL were strongly Thy-1 +, regardless of which NK-augmenting  agent was used. 
The  majority of liver-derived LGL  were also positive for Gma-1.2, a  myelomon- 
ocytic antigen (44), as well as for the Mac-1 (45) and/or  M57 (46) markers (Table 
III).  The  enriched  LGL  population  were  also routinely weakly positive for  Fc WILTROUT ET  AL.  1441 
TABLE III 
Antigenic Phenotype of LGL Isolated  from Mouse Liver 
Cell surface  markers 
Treatment in vivo 
MVE-2  C. parvum 
Ly-1  -  - 
Lyt-2  -  - 
L3T4  -  ND* 
Ly-5  +  + 
Thy-1  +  + 
asGM1  +  ND 
Qa-5  +  + 
Gma-1  +  ND 
Mac-I/M57  +  ND 
sIg  -  - 
* ND, not determined. 
receptors and negative for surface Ig (sIg-). A summary of these results is shown 
in  Table  III.  Regardless  of the  augmenting agent that  was  used,  the  highly 
enriched fraction 1 hepatic LGL were devoid of several specific T  cell markers 
such as Ly-1, Lyt-2, and L3T4 (47) (Table III). The presence of these markers 
might have indicated in vivo expansion or induction of a nonspecific cytolytic T 
cell population similar to the in vitro interleukin 2-expanded cells described by 
others (48,  49).  Conversely, the T  cell-enriched fraction 4  is strongly positive 
for Ly-1, exhibits only low amounts of asGMh and is negative for Qa-5 and Gma- 
1 (Fig. 6). 
Discussion 
This paper describes the isolation and characterization of large numbers of 
NK-active cells from the livers of mice treated with the BRMs MVE-2  and C. 
parvum.  These results are of particular interest since vital organs, including the 
liver,  are  often  sites  of  tumor  metastasis  formation.  We  have  previously 
postulated  3 that  the  normally occurring or  BRM-induced NK activity within 
these nonlymphoid organs may serve as an important component of the natural 
resistance to metastasis formation. In support of  this postulate, we have correlated 
the induction of augmented organ-associated NK activity with immunoprophy- 
latic  resistance  to  the  formation  of experimental  metastases,  which  further 
suggests the  importance of these  cells in  organ-associated antitumor immune 
defense mechanisms. 
The present studies have demonstrated that cells isolated from the livers of 
normal mice had low NK activity, while administration of MVE-2 or C. parvum 
dramatically augmented NK activity in the cells isolated from the liver (Figs.  1- 
3).  It should be  emphasized that the majority of these cells  isolated from the 
liver are not circulating PBL, but represent a population consisting of some cells 
strongly adherent to the vascular endothelium (not removed by extensive per- 
fusion),  and  many cells  already extravasated  into  the  liver  interstitium.  The 
evidence that argues against a significant contamination by PBL includes a lack 
of erythrocyte contamination in  the enzymatically digested liver preparations. 1442  ISOLATION  OF  LARGE  GRANULAR  LYMPHOCYTES  FROM  LIVER 
Additionally, the augmentation of NK activity in blood is much smaller than that 
seen  with  leukocytes  from  liver  preparations. ~ Furthermore,  these  increased 
levels of liver-associated  NK activity correlated  directly with  the adherence  of 
mononuclear cells to the microvasculature of both lung and liver with subsequent 
pronounced  mononuclear  cell  infiltration  into  the  liver  tissue,  detectable  by 
histological  examination  (Wiltrout,  R.  H., and  C.  W.  Reynolds, manuscript  in 
preparation).  These  results  are  consistent  with  the  large  increase  in  the  total 
number  of cells  isolated  from  the  livers  of BRM-treated  mice,  and  strongly 
suggest  that  many  of these  cells are  liver-associated  NK  cells involved  in  the 
organ-associated immune defenses. 
Although  our previous results had  demonstrated  the  presence of NK-active 
lymphocytes  in  nonlymphoid  organs,  and  associated  their  presence  with  the 
therapeutic effects of MVE-2, the nature of the liver-associated NK-active cells 
remained unclear. Therefore, to address this issue, we characterized the specific- 
ity of these BRM-induced, liver-associated cytolytic cells. The cytotoxic selectivity 
of these  liver-derived  cells  was  characteristic  for  NK  activity  (35,  36),  with 
efficient lysis of YAC-1  but not of NK-resistant tumor cells in 4 h (Fig.  5). This 
cytotoxicity was greatly reduced by a single administration  of the NK-suppressive 
anti-asGM1  serum  (Fig.  4)  and  could  be  completely  eliminated  by a  double- 
treatment  regimen  (data  not  shown).  In  contrast,  normal  mice had  moderate 
levels of NC activity, which were neither augmented by MVE-2 nor reduced by 
treatment  with anti-asGM~  serum (Fig.  4).  Therefore,  MVE-2 induced an aug- 
mentation of NK but not NC activity. 
Since NK activity in lymphoid tissue has been associated with LGL (8, 9,  16- 
18), we performed studies to determine if the presence of NK-active cells from 
perfused  livers of MVE-2-treated  mice  might  be associated with  LGL.  These 
studies revealed that  some of the increase in mononuclear cells in the livers of 
MVE-2-treated mice was at least partially due to LGL (Tables I and II) and that 
the enrichment for LGL (fraction 1) correlated with greatly increased NK activity 
(Table II).  Further  evidence for a  role of LGL in liver NK activity came from 
experiments  with  anti-asGM~  serum  treatment  in  vivo,  which  decreased  NK 
activity by >60% and the total number of LGL present in livers from MVE-2- 
treated mice (Table II) by ~90%. 
It should be noted that treatment with MVE-2 did not increase liver-associated 
NC  activity  on  a  per  cell  basis  (Fig.  4).  However,  there  was  an  appreciable 
increase in the total number of cells isolated from the livers of MVE-2-treated 
mice. Therefore,  there was also an increase in the total NC per liver following 
MVE-2  administration.  In  addition,  although  anti-asGM~  treatment  decreased 
NK  activity,  it  did  not  decrease  NC  activity.  This  result  demonstrates  that 
although MVE-2 induced an increase in the total NC activity per liver, these NC 
cells were not sensitive to treatment with anti-asGM1  serum.  The lack of effect 
by anti-asGMl in reducing NC activity confirms a previous observation by Lattime 
et  al.  (50),  and  extends  these  findings  to  tissue-associated  NC  activity,  which 
indicates that anti-asGMa serum may be a useful reagent for further delineating 
the cell types responsible for NK or NC activities and their relative antimetastatic 
capabilities in vivo. 
Although several cell surface markers such as Ly-5 (T-200), Qa-5, and asGMl WILTROUT ET AL.  1443 
(32,  37,  38,  40,  42,  51) have been reported to be present on NK cells in  the 
mouse,  the  phenotypic  characterization of mouse  LGL  has  proceeded more 
slowly than  has  the  study  of rat  or  human  LGL.  In  fact,  most  of the  NK 
phenotype data to date have depended on selective cytolytic elimination (41, 42, 
43,  52) or positive selection techniques that have been capable of selecting for 
only  one  marker at  a  time  (37,  53).  Perhaps  the  greatest  limitation  in  the 
characterization of the cell surface phenotype of mouse NK cells has been the 
difficulty obtaining  highly  purified  cell  populations  in  sufficient numbers  to 
perform careful phenotypic analyses. Attempts to obtain mouse LGL by density 
sedimentation in BSA or Percoll have yielded low numbers of cells and/or only 
partially  enriched  LGL  populations.  In  contrast,  the  ability  to  obtain  large 
numbers of highly purified LGL from the livers of mice treated with MVE-2 has 
allowed us to better characterize these mouse LGL. 
The surface phenotype of LGL obtained from the livers of MVE-2-treated 
mice was asGM  +, Thy-1 +, Mac-1 +, weakly Qa-5 + and Gma-1 +, and Ly-l-, Lyt- 
2-,  L3T4-, and sIg-.  With one exception, the liver LGL were quite similar in 
expression of surface markers to NK-active cells isolated from blood and spleen. 
However, the liver-derived LGL were brightly Thy-1 + as assessed by FCA (Table 
III, Fig. 6), whereas previous data by cytolysis (26, 41, 42, 43,  50, 52) and our 
own  studies  by  FCA  (Mathieson,  B. J.,  R.  Winkler,  W.  R.  Overton,  and  L. 
Mason,  manuscript in  preparation)  would indicate that  blood and spleen  NK 
cells or LGL express much lower amounts of Thy-1. 
Finally, macrophage/myelomonocytic antigens have been recognized on hu- 
man peripheral blood LGL (14) and associated with mouse NK activity (45, 46), 
but  their  expression  on  LGL  from  other nonlymphoid organs  has  not  been 
examined. Thus,  our findings that  the liver LGL express these antigens may 
reflect further heterogeneity associated with either the activation state or the 
lineage(s) of LGL. 
In contrast to peripheral blood or spleen NK cells, much less is known about 
the phenotype of other tissue-associated LGL. In a small number of experiments, 
NK-active cells have been isolated from the lungs (54) and small intestine (19), 
and  these  cells  have  been  characterized  for  cytotoxic  function,  cell  surface 
phenotype, and morphology. Stein-Streilein et al.  (54) have demonstrated the 
presence of NK-active cells in  the lungs of mice infected intratracheally with 
influenza virus, as well as a local augmentation of NK activity in the lung. The 
cells mediating this virus-augmented NK activity expressed asGM1  and Ly-5, as 
did our highly active LGL isolated from the livers of BRM-treated mice. How- 
ever,  the  liver  LGL  were strongly  Thy-1 ÷,  while  lung  NK-active  cells  were 
reported to  be  Thy-1- (54).  By contrast,  gut-associated  LGL,  with  high  NK 
activity, have been reported to be Thy-1 +, but asGM1  negative (19). Therefore, 
the  LGL  population  isolated  from  the  liver  following  MVE-2  or  C.  parvum 
treatment appears functionally similar in terms of target cell specificity (Figs.  2 
and 5),  but phenotypically distinct from other tissue-associated sources of NK- 
active cells. 
Overall, the findings that NK-active cells from spleen, blood, lung, gut, and 
liver are phenotypically similar, but not identical, further emphasize the possible 
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may reflect different maturational  states of NK cells or, alternatively,  different 
NK phenotypes may be determined  by the activation  state of a  single lineage. 
Different stimuli, such as viruses (in the lung [54]) or MVE-2 (in lung and liver) 
may induce  LGL to achieve different activation  stages,  which result in altered 
phenotype.  Alternatively,  the results may indicate stable heterogeneity of NK- 
active cell  subsets or lineage in  various anatomical  compartments.  At present, 
the data to distinguish between these alternatives are not available. 
The  basis  for  the  greatly  augmented  NK activity and  LGL  number  in  the 
livers  of mice  treated  with  MVE-2  or  C.  parvum  is  not  completely  resolved. 
There are three obvious possibilities for this augmentation of hepatic NK activity. 
First,  we have studied the effects of the enzyme cocktail, used to dissociate the 
tissues, on the NK activity of normal spleen cells. Like Stein-Streilein et al. (54), 
we have observed no augmentation  of NK activity following enzyme treatment, 
and therefore conclude that the increased NK activity associated with the liver 
was not a  result of the enzyme treatment  augmenting pre-existent  NK activity. 
In addition,  the large increase in LGL number could not possibly be attributed 
to the enzyme treatment. The second possible explanation for an increase in NK 
activity in  the  liver is that  there was some NK activity present  in  the livers of 
normal  mice,  and  that  the  administration  of certain  BRMs  may  induce  the 
proliferation and activation of a  pre-existent liver LGL pool. The proliferation 
of NK cells in response to virus infections has previously been reported (55), and 
we have preliminary data which would suggest that the number of cells in G1-S 
phase is increased in MVE-2-treated mice over what might be expected in normal 
mice (Wiltrout,  R.  H., and J.  R.  Ortaldo,  unpublished observation).  However, 
the rate of proliferation induced by MVE-2 appears to be insufficient to account 
for the rapid increase in the number of LGL and NK activity. The third possibility 
for the increase in liver NK activity following BRM treatment would be a rapid 
influx of LGL from the blood. To address this possibility, we have done extensive 
histological analyses of the liver as a function of time after MVE-2 or C. parvum 
administrations.  These studies have revealed a large influx of mononuclear cells 
extravasating  into the interstitium  of the liver by 3 d  (Wiltrout,  R. H., and C. 
W.  Reynolds,  manuscript  in  preparation).  This  increase  in  mononuclear  cell 
infiltration corresponded to the large increases in LGL number and NK activity 
(Tables I and  II and  Figs.  1-3).  It therefore appears  that  the increase in  LGL 
number and NK activity in the liver is a result of both proliferation and increased 
LGL  localization.  The  major  effect  is  most  likely  a  result  of an  increased 
lymphocyte infiltration  into the liver, possibly caused by the depot of MVE-2 in 
the liver (56). 
There  are  several  potentially  important  implications  of BRM-induced  LGL 
accumulation in nonlymphoid organs. First, these cells can be highly effective in 
inhibiting  the  formation  of metastases  in  these  organs. 3 Second,  an  influx  of 
LGL may also be of considerable relevance to the therapy of viral diseases. Stein- 
Streilein  et al.  (54) have  demonstrated  a  compartmentalized  augmentation  of 
NK  activity  in  the  lungs  as  a  result  of influenza  virus.  This  augmented  NK 
activity may be important on the eventual resolution of virus infections. In fact, 
Bukowski et al. (57) have demonstrated that depletion of NK activity enhances 
virus-induced hepatitis and virus synthesis in vivo. Further,  these authors have WlLTROUT  ET  AL.  1445 
noted enhanced tumor rejection and augmented NK activity in mice persistently 
infected with lymphocytic choriomeningitis virus (58). Cumulatively, these results 
suggest a potentially important role for tissue LGL in the resistance to metastases 
and viral diseases. 
In summary, this study shows that the BRMs MVE-2 and C. parvum can induce 
greatly augmented NK activity in the liver. This increased liver-associated NK 
activity is due to an increase in LGL that have a surface phenotype similar, but 
not identical,  to  previously characterized murine LGL populations.  The  liver 
should therefore provide a  source of LGL in  high purity that can be used to 
study numerous aspects of activated LGL function and biology in the mouse. 
Finally, the observation of an increased tissue-associated NK activity that strongly 
correlates with our previous observations regarding a decrease in tumor metas- 
tases following BRM injection suggests that some BRMs can induce an increase 
in tissue-associated immune responses that may have direct therapeutic or clinical 
implications for neoplastic and/or virus-induced diseases. 
Summary 
Natural killer (NK) activity in the rat and human has been attributed to cells 
having the  morphology of large  granular  lymphocytes (LGL).  However,  this 
association has been  less  clear in  the mouse, largely because of difficulties in 
obtaining highly enriched populations of LGL from normal spleen and blood. 
We have previously observed that the administration of the biological response 
modifier (BRM)  maleic anhydride divinyl ether (MVE-2) strongly augmented 
NK activity in  lung and liver, and the augmented NK activity coincided with 
increased resistance to the formation of experimental metastases in these organs. 
The degree of NK augmentation was most striking in the liver, an unexpected 
and previously unreported observation.  In the present study, both  MVE-2  or 
Corynebacterium parvum induced a dramatic augmentation of liver NK activity, 
which reached maximum levels 3-5 d after treatment. This augmentation of NK 
activity in the liver coincided with a  large increase in the number of lymphoid 
cells with the morphological characteristics of LGL that could be isolated from 
enzymatically digested suspensions of perfused liver. The yield of LGL per liver 
following BRM treatment corresponded to a  10-50-fold increase as compared 
to normal mice. LGL were purified from these enzymatically  digested suspensions 
of perfused  liver by depletion  of adherent cells on  nylon  wool columns and 
subsequent enrichment for low-density lymphoid cells by fractionation on Percoll 
density gradients. The enrichment of LGL correlated with greatly increased NK 
activity against YAC-1. Conversely, the higher-density fractions were depleted 
of both  LGL  and  NK  activity. This  increase in  NK  activity in  the  liver was 
suppressed  by  in  vivo  treatment  with  anti-asialo  GM~  (asGM1)  serum.  This 
treatment also resulted in a corresponding reduction in both the total number 
and  percentage  of  LGL.  By  flow  cytometry analysis,  the  phenotype  of the 
majority of these highly cytolytic LGL isolated from the livers of BRM-treated 
mice were asGMi +, Thy-1 ÷, Ly-5  +, Qa-5 ÷, Mac-1 +, and Gma-1 +, whereas these 
LGL were Ly-l-, Lyt-2-, L3T4-, and surface Ig-. We conclude that the livers 
of BRM-treated mice can provide a rich source of highly active mouse LGL that 
could be used for further characterization of this lymphocyte subset.  Further, 1446  ISOLATION OF  LARGE  GRANULAR  LYMPHOCYTES  FROM  LIVER 
these studies  imply a  potential  for  BRM  therapy of neoplastic  or  viral diseases 
through augmentation of organ-associated immune responses. 
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